Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Yoshiyuki Morishima, PhD, Yuko Honda, Taketoshi Furugohri, PhD

Blood (2018) 132 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2018-99-109724

Published: 2018

Journal Articles

Anti-Inhibitor Coagulant Complex, Prothrombin Complex Concentrate, and Recombinant Factor VIIa Reverse Prothrombin Time Prolonged by Edoxaban In Human Plasma

Yoshiyuki Morishima, Ph.D., Yuko Honda, Toshiro Shibano, Ph.D.

Blood (2010) 116 (21): 3319.

https://doi.org/10.1182/blood.V116.21.3319.3319

Published: 2010

Journal Articles

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

Toshio Fukuda, Yuko Honda, Chikako Matsumoto, Nobutoshi Sugiyama, PhD, Tadashi Matsushita, PhD, Masamitsu Yanada, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2005) 106 (11): 1874.

https://doi.org/10.1182/blood.V106.11.1874.1874

Published: 2005

Journal Articles

A Thrombin Inhibitor, but Not a Factor Xa Inhibitor, DU-176b, Aggravates Tissue Factor-Induced Hypercoagulation in Rats.

Yoshiyuki Morishima, PhD, Toshio Fukuda, Naoki Tsuji, PhD, Yuko Honda, Chikako Matsumoto, Taketoshi Furugohri, Toshiro Shibano, PhD

Blood (2005) 106 (11): 1878.

https://doi.org/10.1182/blood.V106.11.1878.1878

Published: 2005

Journal Articles

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Taketoshi Furugohri, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1851.

https://doi.org/10.1182/blood.V104.11.1851.1851

Published: 2004

Journal Articles

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

Toshio Fukuda, Chikako Matsumoto, Yuko Honda, Nobutoshi Sugiyama, PhD, Yoshiyuki Morishima, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1852.

https://doi.org/10.1182/blood.V104.11.1852.1852

Published: 2004

Journal Articles

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Yoshiyuki Morishima, PhD, Taketoshi Furugohri, Koji Isobe, Yuko Honda, Chikako Matsumoto, Yoko Shiozaki, Sumie Muramatsu, Nobutoshi Sugiyama, PhD, Toshiro Shibano, PhD

Blood (2004) 104 (11): 1862.

https://doi.org/10.1182/blood.V104.11.1862.1862

Published: 2004

NARROW

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Anti-Inhibitor Coagulant Complex, Prothrombin Complex Concentrate, and Recombinant Factor VIIa Reverse Prothrombin Time Prolonged by Edoxaban In Human Plasma

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

A Thrombin Inhibitor, but Not a Factor Xa Inhibitor, DU-176b, Aggravates Tissue Factor-Induced Hypercoagulation in Rats.

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Email alerts

ASH Publications

American Society of Hematology

A Direct Oral Anticoagulant Edoxaban Enhanced Fibrinolysis Via Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor Activation and Enhancement of Plasmin Generation in Human Plasma

Anti-Inhibitor Coagulant Complex, Prothrombin Complex Concentrate, and Recombinant Factor VIIa Reverse Prothrombin Time Prolonged by Edoxaban In Human Plasma

Impact of Antithrombin Deficiency on Efficacies of DU-176b, a Novel Orally Active Direct Factor Xa Inhibitor, and Antithrombin Dependent Anticoagulants, Fondaparinux and Heparin.

A Thrombin Inhibitor, but Not a Factor Xa Inhibitor, DU-176b, Aggravates Tissue Factor-Induced Hypercoagulation in Rats.

Antithrombotic and Hemorrhagic Effects of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor: A Wider Safety Margin Compared to Heparins and Warfarin.

Antithrombotic Properties of DU-176b, a Novel, Potent and Orally Active Direct Factor Xa Inhibitor in Rat Models of Arterial and Venous Thrombosis: Comparison with Fondaparinux, an Antithrombin Dependent Factor Xa Inhibitor.

In Vitro Characteristics, Anticoagulant Effects and In Vivo Antithrombotic Efficacy of a Novel, Potent and Orally Active Direct Factor Xa Inhibitor, DU-176b.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only